Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. VITA 34 AG
  6. Summary
    V3V   DE000A0BL849

VITA 34 AG

(V3V)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
11/30/2021 12/01/2021 12/02/2021 12/03/2021 12/06/2021 Date
16.9(c) 17(c) 16.5(c) 16.45(c) 16.5 Last
1 577 7 016 1 844 306 10 016 Volume
+0.90% +0.59% -2.94% -0.30% +0.30% Change
More quotes
Estimated financial data (e)
Sales 2021 22,0 M 24,8 M 24,8 M
Net income 2021 1,85 M 2,09 M 2,09 M
Net cash position 2021 7,90 M 8,91 M 8,91 M
P/E ratio 2021 36,2x
Yield 2021 0,49%
Sales 2022 23,7 M 26,7 M 26,7 M
Net income 2022 3,20 M 3,61 M 3,61 M
Net cash position 2022 11,8 M 13,3 M 13,3 M
P/E ratio 2022 21,1x
Yield 2022 0,61%
Capitalization 264 M 298 M 298 M
EV / Sales 2021 11,6x
EV / Sales 2022 10,7x
Nbr of Employees 124
Free-Float 83,9%
More Financials
Company
Vita 34 International AG is a Germany-based company engaged in the medical technology sector. The Company is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected at the childÔÇÖs birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after... 
More about the company
Ratings of VITA 34 AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about VITA 34 AG
11/11Vita 34 again increases sales and margins in the third quarter
EQ
11/11VITA 34 AG Reports Earnings Results for the Third Quarter and Nine Months Ended Septemb..
CI
11/09Vita 34 AG Announces Withdrawal of Guidance for Financial Year 2021
CI
10/11VITA 34 : extends the acceptance period under PBKM exchange offer
EQ
09/20VITA 34 : Commences Offer Period for Polski Bank Komorek Takeover
MT
09/20VITA 34 : launches voluntary public exchange offer for PBKM shares
EQ
08/31VITA 34 : again achieves double-digit growth in revenues and earnings in the first half of..
EQ
08/31VITA 34 AG Affirms Earnings Guidance for the Full Fiscal Year 2021
CI
08/31VITA 34 AG Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
08/16VITA 34 : Names New CFO
MT
08/16VITA 34 AG : Andreas Schafhirt appointed as new Chief Financial Officer of Vita 34 AG
EQ
08/16VITA 34 AG Announces Chief Financial Officer Changes
CI
05/31VITA 34 : publishes figures for the first quarter of 2021
EQ
05/31VITA 34 AG Provides Earnings Guidance for the Year 2021
CI
05/31VITA 34 : Polski Bank Komorek Agree To Merge Via Share Swap
MT
More news
News in other languages on VITA 34 AG
08:37aVITA 34 AG : Veröffentlichung gemäß ž 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbrei..
11/26VITA 34 AG : Veröffentlichung gemäß ž 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbrei..
11/24VITA 34 AG : Veröffentlichung gemäß ž 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbrei..
11/24VITA 34 AG : Meldung und öffentliche Bekanntgabe der Geschäfte von Personen
11/24Vita 34 AG
More news
Chart VITA 34 AG
Duration : Period :
VITA 34 AG Technical Analysis Chart | V3V | DE000A0BL849 | MarketScreener
Technical analysis trends VITA 34 AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 16,45 €
Average target price 19,10 €
Spread / Average Target 16,1%
EPS Revisions
Managers and Directors
Wolfgang Knirsch Chairman-Management Board
Andreas W. Schafhirt Chief Financial Officer
Florian M. Schuhbauer Chairman-Supervisory Board
Steffen Richtscheid Deputy Chairman-Supervisory Board
Frank K÷hler Member-Supervisory Board
Sector and Competitors